Information Provided By:
Fly News Breaks for November 12, 2019
Nov 12, 2019 | 14:33 EDT
Jefferies analyst Michael Yee addressed some of the takeaways from "another short report" on FibroGen (FGEN), which he doesn't think includes "anything new." He has previously said that he expects ongoing "noise and confusion" about cardiovascular events in various populations, though he has talked to FibroGen, AstraZeneca (AZN) and many doctors and investigators, who "support a clear view of approval and safety here." The newest short report published on FibroGen highlights topics that are "generally known or mentioned in our previous reports," added Yee, who has a Buy rating on the shares.